Matinas Biopharma Holdings, Inc. (MTNB) got here out with a quarterly lack of $0.04 per share versus the Zacks Consensus Estimate of a lack of $0.03. This compares to lack of $0.03 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of -33.33%. 1 / 4 in the past, it was anticipated that this firm would submit a lack of $0.03 per share when it really produced a lack of $0.03, delivering no shock.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.
Matinas Biopharma Holdings, Inc.Which belongs to the Zacks Medical – Medication business, posted zero revenues for the quarter ended December 2019, lacking the Zacks Consensus Estimate by 100%. This compares to zero revenues a 12 months in the past.
The sustainability of the inventory’s fast worth motion based mostly on the recently-released numbers and future earnings expectations will principally…